Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Liminatus Pharma ( (LIMN) ) has provided an announcement.
On July 16, 2025, Liminatus Pharma, Inc. entered into a settlement agreement with Alta Partners, LLC, where the company agreed to issue 350,000 shares of its common stock in exchange for the cancellation of 1,000,000 warrants held by Alta Partners. This strategic move, involving no commission or remuneration, reflects Liminatus Pharma’s efforts to manage its equity structure and could have implications for its stock valuation and investor relations.
More about Liminatus Pharma
Average Trading Volume: 334,519
Technical Sentiment Signal: Sell
Current Market Cap: $145.4M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges